Organization (Hospital)
Scripps Health
ClinicalTrials.gov lists Scripps Health as lead sponsor of 73 trials, counting the companies grouped under it. Scripps Health itself has 20 active development programs and 20 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Scripps Health and 2 companies grouped under it: 73 lead-sponsored trials (48 its own, 25 in the grouped companies) and 3 legal-entity registrations (1 its own, 2 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Scripps Whittier Diabetes Institute | 19 | 1 |
| Scripps Clinic | 6 | 1 |
Disease areas (141)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 19 |
| Diabetes Mellitus, Type 2 | 14 |
| Pain | 6 |
| Coronary Artery Disease | 5 |
| Coronary Disease | 5 |
Showing 5 of 141 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 5 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 4 |
Showing 10 of 23 years.
Prediction, not a registry value: median of 31 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 26 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (20)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Duloxetine 60 MG | Postoperative Pain | Phase 2 | 1 |
| Duloxetine 60 MG | Substance-Related Disorders | Phase 2 | 1 |
| Duloxetine 60 MG | Pain | Phase 2 | 1 |
| Duloxetine 60 MG | Opioid-Related Disorders | Phase 2 | 1 |
| Duloxetine 60 MG | Chronic Pain | Phase 2 | 1 |
Showing 5 of 20 active programs.
Approved assets (20)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Aspirin and Clopidogrel | 1 |
| Reduced duration (6 months) DAPT | 1 |
| Dapagliflozin | 1 |
| 5000 Units unfractionated Heparin Q 8 hr | 1 |
| 30mg enoxaparin Q12 hr | 1 |
Showing 5 of 20 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 18% hit target (n=17) | 64% on time (n=14) |
Journals published in (141)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 10 |
| American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons | 9 |
| Circulation | 9 |
| Ophthalmology | 6 |
| The American journal of sports medicine | 5 |
Showing 5 of 141 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 18 | 7 | 2025-03-11 |
Financing and grant events (13)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-16 | NIH grant | 165,541 | Reporter |
| 2025-07-23 | NIH grant | 646,559 | Reporter |
| 2025-06-03 | NIH grant | 615,143 | Reporter |
| 2024-11-14 | NIH grant | 317,259 | Reporter |
| 2024-08-26 | NIH grant | 673,579 | Reporter |
Showing 5 of 13 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 4 |
Organization relationships (17)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Scripps Translational Science Institute | Co sponsors trial with | 2 |
| Lexent Bio, Inc. | Co sponsors trial with | 1 |
| Research Center on Computational BioMarkers | Co sponsors trial with | 1 |
| Burl Concepts, Inc. | Co sponsors trial with | 1 |
| IRCCS Centro San Giovanni di Dio Fatebenefratelli | Co sponsors trial with | 1 |
Showing 5 of 17 relationships.
Latest dated events (131)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 131 events.
Biomarker capability evidence (60)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| BCHE | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial collaborator | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 60 evidence rows.
Biomarkers this organization publishes on (73)
Shown in this order: most publications first.
Showing 5 of 73 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.